Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lisata Therapeutics (LSTA) EBIT Margin (2016 - 2025)

Lisata Therapeutics filings provide 11 years of EBIT Margin readings, the most recent being 2368.46% for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin fell 187356.0% year-over-year to 2368.46%, compared with a TTM value of 9104.0% through Dec 2025, down 686310.0%, and an annual FY2025 reading of 9104.5%, down 686360.0% over the prior year.
  • EBIT Margin hit 2368.46% in Q4 2025 for Lisata Therapeutics, up from 6954.29% in the prior quarter.
  • The five-year high for EBIT Margin was 494.9% in Q4 2024, with the low at 6954.29% in Q2 2025.